Department of Dermatology, University of Michigan Medical School and Comprehensive Cancer Center, Ann Arbor.
Department of Dermatology, University of Michigan Medical School and Comprehensive Cancer Center, Ann Arbor2Department of Pathology, University of Michigan Medical School and Comprehensive Cancer Center, Ann Arbor.
JAMA Otolaryngol Head Neck Surg. 2016 Dec 1;142(12):1171-1176. doi: 10.1001/jamaoto.2016.1927.
Metastasis of cutaneous squamous cell carcinoma (SCC) to the nodal basin is associated with a poor prognosis. The role of sentinel lymph node biopsy (SLNB) for regional staging in patients diagnosed with SCC is unclear.
To evaluate a single institution's experience with use of SLNB for regional staging of SCC on the head and neck.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of 53 patients who were diagnosed with SCC on the head and neck, at high risk for nodal metastasis based on National Comprehensive Cancer Network (NCCN) risk factors, and treated with wide local excision (WLE) and SLNB from December 1, 2010, through January 30, 2015, in a single academic referral center was performed. The follow-up period ended November 5, 2015. Sentinel lymph node biopsy paraffin blocks were retrieved and processed retrospectively with serial sectioning and immunohistochemical analysis (IHC) in cases with nodal recurrence following a negative SLNB.
Sentinel node (SN) identification rate, SLNB positivity rate, local recurrence, regional nodal recurrence, and distant recurrence.
In 53 patients with 54 tumors the SN identification rate was 94%. The SLNB positivity rate was 11.3%. On more thorough tissue processing and IHC, metastatic SCC was identified in 2 of 5 (40%) cases previously deemed negative. After reclassification of these cases, the adjusted SLNB positivity rate was 15.1%. The adjusted rate of false omission was 7.1% (95% CI, 2%-19%). Nodal disease developed in 20.8% overall. Angiolymphatic invasion (Cohen d, 3.52; 95% CI, 1.83-5.21), perineural invasion (Cohen d, 0.81; 95% CI, 0.09-1.52), and clinical size (Cohen d, 0.83; 95% CI, 0.05-1.63) were associated with the presence of nodal disease.
Rigorous study of SLNB for cutaneous SCC incorporating prospectively-collected comprehensive data sets based on standardized treatment algorithms is justified with potential to modify clinical practice. Our study demonstrates the critical importance of serial sectioning and IHC of the SLNB specimen for accurate diagnosis. Use of the NCCN guidelines may facilitate identification of patients with SCC at high risk for nodal metastasis.
皮肤鳞状细胞癌(SCC)转移至淋巴结区与预后不良相关。对于基于美国国家综合癌症网络(NCCN)风险因素诊断为 SCC 且有区域转移风险的患者,行前哨淋巴结活检(SLNB)进行区域分期的作用尚不明确。
评估单中心应用 SLNB 对头颈部 SCC 进行区域分期的经验。
设计、地点和患者:对 2010 年 12 月 1 日至 2015 年 1 月 30 日期间于单家学术转诊中心因高风险发生淋巴结转移(基于 NCCN 风险因素)而接受广泛局部切除术(WLE)和 SLNB 治疗的 53 例头颈部 SCC 患者进行回顾性分析。随访截止日期为 2015 年 11 月 5 日。对 SLNB 阴性但发生淋巴结复发的病例,对 SLNB 石蜡块进行了回顾性检索和处理,并行连续切片和免疫组化分析(IHC)。
前哨淋巴结(SN)检出率、SLNB 阳性率、局部复发率、区域淋巴结复发率和远处复发率。
53 例患者 54 个肿瘤中,SN 检出率为 94%。SLNB 阳性率为 11.3%。在对更彻底的组织处理和 IHC 结果进行分析后,在 2 例(40%)先前被认为阴性的病例中发现了转移性 SCC。对这些病例进行重新分类后,SLNB 阳性率调整为 15.1%。假阴性率为 7.1%(95%CI,2%19%)。总体上有 20.8%的患者发生了淋巴结疾病。血管淋巴管侵犯(Cohen d,3.52;95%CI,1.835.21)、神经周围侵犯(Cohen d,0.81;95%CI,0.091.52)和临床大小(Cohen d,0.83;95%CI,0.051.63)与淋巴结疾病有关。
采用基于标准化治疗算法的前瞻性收集全面数据集的严格 SLNB 研究对头颈部 SCC 具有合理性,可能会改变临床实践。本研究证明了对 SLNB 标本进行连续切片和 IHC 的重要性,这有助于准确诊断。使用 NCCN 指南可能有助于识别 SCC 转移风险较高的患者。